Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protara Therapeutics, Inc. - Common Stock (NQ:TARA)

3.960 +0.110 (+2.86%)
Streaming Delayed Price Updated: 2:16 PM EDT, Apr 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 957,789
Open 3.900
Bid (Size) 3.960 (5)
Ask (Size) 3.990 (3)
Prev. Close 3.850
Today's Range 3.780 - 4.050
52wk Range 1.595 - 10.48
Shares Outstanding 11,235,731
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga

Performance

YTD
-29.0%
-29.0%
1 Month
-15.7%
-15.7%
3 Month
-16.8%
-16.8%
6 Month
+97.0%
+97.0%
1 Year
+29.8%
+29.8%

More News

Read More
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Recap: Protara Therapeutics Q1 Earnings
Via Benzinga
Protara Therapeutics Releases Early Cut Data From Investigational Cell-Based Therapy For Bladder Cancer
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Crude Oil Edges Lower; US Initial Jobless Claims Increase
Via Benzinga
Exposures Fossil Fuels
Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?
Via Benzinga
Dow Falls 50 Points; Kroger Posts Downbeat Sales
Via Benzinga
Topics Stocks
Exposures US Equities
TARA Stock Earnings: Protara Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
TARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
3 Stocks That Could Help You Retire on a Private Island
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Protara Therapeutics: Q3 Earnings Insights
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga

Frequently Asked Questions

Is Protara Therapeutics, Inc. - Common Stock publicly traded?
Yes, Protara Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Protara Therapeutics, Inc. - Common Stock trade on?
Protara Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Protara Therapeutics, Inc. - Common Stock?
The ticker symbol for Protara Therapeutics, Inc. - Common Stock is TARA on the Nasdaq Stock Market
What is the current price of Protara Therapeutics, Inc. - Common Stock?
The current price of Protara Therapeutics, Inc. - Common Stock is 3.960
When was Protara Therapeutics, Inc. - Common Stock last traded?
The last trade of Protara Therapeutics, Inc. - Common Stock was at 04/22/25 02:16 PM ET
What is the market capitalization of Protara Therapeutics, Inc. - Common Stock?
The market capitalization of Protara Therapeutics, Inc. - Common Stock is 44.49M
How many shares of Protara Therapeutics, Inc. - Common Stock are outstanding?
Protara Therapeutics, Inc. - Common Stock has 44M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.